STOCK TITAN

Farallon group (NASDAQ: NERV) discloses 4.54M Minerva Neurosciences shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Minerva Neurosciences, Inc. received an updated ownership report from Farallon-managed funds. The Farallon Funds together hold 2,365,000 common shares of Minerva and 5,000 Tranche A warrants, each warrant exercisable into one share of Series A convertible voting preferred stock.

Each Series A preferred share is convertible into 473 common shares, subject to a 9.99% Beneficial Ownership Limitation, which currently allows conversion into up to 2,174,854 common shares. Farallon Partners, L.L.C. reports beneficial ownership of 4,316,598 shares, or 9.5% of the common stock. Several Farallon individual reporting persons, including Joshua J. Dapice and others, each report beneficial ownership of 4,539,854 shares, or 9.99% of the class.

The amendment also notes that effective January 1, 2026, Avner A. Husen became a member or manager of the Farallon general partner entities, while effective December 31, 2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles. The reporting group certifies the holdings are not for the purpose of changing or influencing control of Minerva.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/05/2026
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/05/2026
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/05/2026
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/05/2026
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:02/05/2026
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/05/2026
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/05/2026
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:02/05/2026
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:02/05/2026
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:02/05/2026
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:02/05/2026
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:02/05/2026
Fried, Richard B
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Husen, Avner A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Patel, Rajiv A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Seybold, William
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/05/2026
Exhibit Information

Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

FAQ

How many Minerva Neurosciences (NERV) shares do the Farallon Funds report owning?

The Farallon Funds report holding 2,365,000 common shares of Minerva Neurosciences and 5,000 Preferred Tranche A Warrants. These warrants are exercisable into Series A convertible voting preferred stock, which in turn can be converted into additional common shares subject to a 9.99% ownership cap.

What percentage of Minerva Neurosciences (NERV) does Farallon report beneficially owning?

Farallon Partners, L.L.C. reports beneficial ownership of 9.5% of Minerva’s common stock, or 4,316,598 shares. Several Farallon individual reporting persons each report 9.99%, corresponding to 4,539,854 shares, reflecting their deemed beneficial ownership through Farallon-managed funds and entities.

How do the Series A Preferred Stock and Tranche A Warrants work for Minerva Neurosciences (NERV)?

Each Preferred Tranche A Warrant is exercisable into one Series A Preferred share, and each Series A Preferred share is convertible into 473 common shares. Conversion is limited by a 9.99% Beneficial Ownership Limitation, capping how many common shares can be acquired at any time.

What is the 9.99% Beneficial Ownership Limitation mentioned for Minerva Neurosciences (NERV)?

The Beneficial Ownership Limitation prevents Series A Preferred Stock from being converted if it would cause the reporting persons to own more than 9.99% of Minerva’s common shares. Under this cap, Farallon may convert into up to 2,174,854 common shares from 4,598 preferred shares.

What changes in Farallon’s internal leadership roles are disclosed regarding Minerva Neurosciences (NERV)?

Effective January 1, 2026, Avner A. Husen became a member or manager of Farallon’s general partner entities and may be deemed a beneficial owner of the Farallon Funds’ Minerva holdings. As of December 31, 2025, Richard B. Fried, Rajiv A. Patel, and William Seybold ceased those roles.

Is the Farallon group seeking control of Minerva Neurosciences (NERV) with this stake?

The reporting persons certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Minerva Neurosciences. They also state the holdings are not in connection with any transaction having that control-related purpose or effect.

Under which SEC rule is this Schedule 13G/A for Minerva Neurosciences (NERV) filed?

The reporting persons state they are filing this Schedule 13G/A pursuant to Rule 13d-1(c). They neither disclaim nor affirm the existence of a group, and each reporting person is a beneficial owner only of the securities reported on that person’s own cover page.